Several other equities analysts have also recently issued reports on the company. Bank of America reissued a neutral rating and issued a $60.00 price objective (up previously from $42.00) on shares of Guardant Health in a report on Thursday, February 28th. JPMorgan Chase & Co. boosted their price objective on Guardant Health from $42.00 to $85.00 and gave the company an overweight rating in a report on Wednesday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus price target of $72.50.
Guardant Health stock opened at $94.45 on Wednesday. The stock has a market cap of $6.35 billion and a price-to-earnings ratio of -33.73. Guardant Health has a fifty-two week low of $27.04 and a fifty-two week high of $98.25.
Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Tuesday, March 12th. The company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.05. The firm had revenue of $32.87 million for the quarter, compared to analysts’ expectations of $24.57 million. As a group, equities research analysts forecast that Guardant Health will post -1.26 earnings per share for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Pendal Group Ltd purchased a new stake in shares of Guardant Health in the fourth quarter worth $213,000. Emerald Advisers LLC purchased a new stake in shares of Guardant Health in the fourth quarter worth $752,000. Kornitzer Capital Management Inc. KS purchased a new stake in shares of Guardant Health in the fourth quarter worth $2,096,000. Rhumbline Advisers purchased a new stake in shares of Guardant Health in the fourth quarter worth $747,000. Finally, Benjamin F. Edwards & Company Inc. purchased a new stake in shares of Guardant Health in the fourth quarter worth $26,000. 69.54% of the stock is owned by institutional investors.
About Guardant Health
Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.
Further Reading: Outstanding Shares, Buying and Selling Stocks
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.